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Although the tyrosine kinase inhibitor imatinib has been shown to be an active agent in patients with gastrointestinal stromal tumours
(GIST), complete remissions are almost never seen and most patients finally experience disease progression during their course of
treatment. An alternative therapeutic option is to target death receptors such as Fas. We showed that a panel of imatinib-sensitive
(GIST882) and imatinib-resistant (GIST48, GIST430 and GIST430K-) cell lines expressed Fas. MegaFasL, a recently developed
hexameric form of soluble Fas ligand (FasL), appeared to be an active apoptosis-inducing agent in these cell lines. Moreover,
MegaFasL potentiated the apoptotic effects of imatinib. Immunohistochemical evaluations, in 45 primary GISTs, underscored the
relevance of the Fas pathway: Fas was expressed in all GISTs and was expressed strongly in 93%, whereas FasL was expressed at
moderate and strong levels in 35 and 53% of GISTs, respectively. Fas and FasL expression were positively correlated in these primary
GISTs, but there was no association between Fas or FasL expression and primary site, histological subtype, tumour size, mitotic index,
risk classification, and KIT mutation status. The abundant immunohistochemical Fas and FasL expression were corroborated by
western blot analysis. In conclusion, our data implicate Fas as a potential therapeutic target in GIST.
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The observation that nearly all spindle cell and epithelial tumours
of the stomach and bowel highly express the receptor tyrosine
kinase KIT has led to the characterisation of gastrointestinal
stromal tumours (GISTs) as a distinct clinicopathological entity
different from other gastrointestinal mesenchymal tumours.
Various KIT genomic mutations occur in about 80% of GISTs. In
addition, about 5% of GISTs have mutations in the platelet-derived
growth factor receptor-a (PDGFRA) (Corless et al, 2004). These
mutations lead to ligand-independent activation of KIT or
PDGFRA, which plays an essential role in the development and
progression of GIST (Heinrich et al, 2002, 2003). As GISTs are
insensitive to conventional chemotherapy, the introduction of
imatinib, a small-molecule receptor tyrosine kinase inhibitor
active against KIT and PDGFRA, has been a major therapeutic
breakthrough. Imatinib therapy has dramatically improved the
survival of patients with unresectable or metastatic GIST (Verweij
et al, 2004). Despite these successes, about 10% of the patients
show initial resistance to imatinib. Moreover, complete remissions
are almost never seen and most patients experience disease
progression after a median period of approximately 2–3 years
(Verweij et al, 2004). To date, sunitinib, an inhibitor of multiple
receptor tyrosine kinases including KIT, PDGFRA, vascular
endothelial growth factor receptor (VEGFR), and fms-related
tyrosine kinase 3 (FLT3), is used as a second-line treatment
providing clinical benefit in patients with imatinib-resistant GIST
for a limited time period (Judson and Demetri, 2007). However,
there is urgent need for the development of new therapeutics
acting through pathways complementary to those targeted by KIT
kinase inhibitors such as imatinib and sunitinib.
Fas (CD95) and Fas ligand (FasL; CD95L) belong to the TNF
family of death receptors and ligands (Itoh et al, 1991; Suda et al,
1993). At the molecular level, binding of FasL to Fas induces
receptor trimerisation, followed by the binding of Fas-associated
death domain (FADD) with caspase 8 and/or 10 to the intracellular
death domain of Fas. Caspase activation within this complex
initiates cleavage and activation of an intracellular cascade of
effector caspases (e.g., caspases 3, 6, and 7), eventuating in
cleavage of specific death substrates and apoptosis (Timmer et al,
2002). Thus, in tumours expressing Fas, targeting of Fas-mediated
apoptosis could be a promising therapy. Although many in vitro
and in vivo cancer models have shown sensitivity towards Fas
agonistic antibodies, clinical application of these antibodies is
hampered because of severe liver toxicity (Ogasawara et al, 1993).
Furthermore, resistance to Fas-mediated apoptosis because of
inhibitory mechanisms along the apoptotic signalling pathway has
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sbeen observed in other cancer models (Houston and O’Connell,
2004). Soluble forms of FasL (sFasL) are potentially less toxic
(Schneider et al, 1998), and a hexameric form of sFasL, produced
by fusing the dimer-forming serum protein stalk of human ACRP30
to the trimeric portion of human FasL, has recently been developed.
This compound, called MegaFasL, is more cytotoxic to tumour
cells compared to trimeric sFasL (Holler et al, 2003; Greaney
et al, 2006; Etter et al, 2007). MegaFasL is currently tested in a
phase-I clinical trial (ClinicalTrails.gov identifier: NCT00437736).
This study was initiated given the lack of data on expression of
Fas and FasL in GIST. Therefore, the sensitivity of GIST cell lines
towards Fas activation and the potentiating effect of imatinib on
this activation were investigated. In addition, the expression of Fas
and FasL in primary GIST samples was studied. Together, these
data implicate Fas as a potential therapeutic target in GIST.
MATERIALS AND METHODS
Cell culture
The GIST cell line GIST882 was developed from a primary,
untreated, GIST, with a homozygous KIT exon 13 mutation
(Tuveson et al, 2001). Cells were maintained in RPMI 1640
(Invitrogen, Praisley, UK) supplemented with 15% heat inactivated
fetal calf serum (FCS; Bodinco, Alkmaar, The Netherlands) and
1m ML -glutamine (Invitrogen). The GIST cell lines GIST48 and
GIST430 were established from tumours that were progressive
during imatinib therapy after an initial clinical response (Bauer
et al, 2006). GIST48 harbours a homozygous primary KIT exon 11
mutation and a heterozygous secondary exon 17 mutation.
GIST430 has a heterozygous primary KIT exon 11 and a secondary
heterozygous exon 13 mutation. The KIT-negative GIST430K- cell
line was derived from GIST430 cells. The GIST48 and GIST430 cells
were maintained in F-10 (Invitrogen) supplemented with 10 and
15% FCS, respectively, and 0.5% mitoþ serum extender (VWR
International, Roden, The Netherlands) and 1% bovine pituitary
extract (VWR International). The cervical carcinoma cell line
HeLa was maintained in 1:1 DMEM/HAM supplemented with 10%
FCS.
Flow cytometry
Fas membrane expression was determined in GIST cells by flow
cytometry as described previously (De Groot et al, 2005).
Phycoerythrin (PE)-conjugated mouse anti-Fas monoclonal anti-
body (clone DX-2, 1:10; BD Pharmingen, Alphen aan de Rijn, The
Netherlands) was used. PE-conjugated mouse IgG1 (BD Pharmin-
gen) served as an isotype control.
Acridine orange apoptosis assay
Cells were treated with MegaFasL (kindly provided by Apoxis,
Lausanne, Switzerland) for 6h. To investigate the effect of
MegaFasL on imatinib-induced apoptosis, cells were pretreated
with imatinib (kindly provided by Novartis, Basel, Switzerland) for
24h followed by 24h incubation with MegaFasL without removing
imatinib. Alternatively, cells were first treated with MegaFasL for
24h with subsequent treatment with imatinib for 24h. Control
cells were incubated with DMSO, which was used as a solvent for
imatinib, where appropriate, or a single drug. After these
treatments, acridine orange (10mgml
 1) was added to each well
to distinguish apoptotic cells from vital cells. Apoptosis was
defined as the appearance of apoptotic bodies and/or chromatin
condensation, using a fluorescence microscope. Results were
expressed as the percentage of apoptotic cells in a culture by
counting at least 300 cells per well. All apoptosis assays were
performed three times in duplicate.
Western blot analysis
After treatment with MegaFasL, as described above, GIST882 and
GIST48 cells were lysed and the protein concentration was
determined according to the Bradford method. Western blotting
was performed as described previously (De Groot et al, 2005).
Primary antibodies were goat anti-Fas (polyclonal, 1:400;
Santa Cruz, Heerhugowaard, The Netherlands), mouse anti-FasL
and mouse anti-caspase 3 (clone 33 and clone 19, respectively,
1:1000; BD Transduction Laboratories, Alphen aan den Rijn,
The Netherlands), rabbit anti-cleaved caspase 3 and rabbit
anti-caspase 6 (1:1000; Cell Signalling Technology, Bioke ´, Leiden,
The Netherlands), mouse anti-caspase 8 (clone 1C12, 1:500; Cell
Signalling), and mouse anti-actin (clone C4, 1:20000; ICN
Biomedicals, Zoetermeer, The Netherlands).
Tissue collection
The study group consisted of 45 primary GISTs derived from 44
patients. Paraffin-embedded tumour tissues of primary GISTs were
retrieved from the files of the Department of Pathology of the
University Medical Center Groningen. Tumours were surgically
resected between 1985 and 2005. All tumours were reviewed by a
pathologist with special expertise in soft tissue tumours (AJHS).
The diagnosis of GIST was based on the typical histological
features of a cellular spindle cell or epithelioid mesenchymal
tumour of the gastrointestinal tract. In addition, all tumours were
positive for CD117 (KIT) by immunohistochemistry. Tumours
were categorised into risk groups, based on tumour size and
mitotic index, according to the consensus classification for
prediction of metastatic potential (Fletcher et al, 2002). Tumour
size was obtained from the pathology reports. Mitotic index was
counted in 50 consecutive high power fields ( 40 objective; field
diameter 0.55mm). Clinicopathological data collected included sex
and age of the patient at diagnosis, primary tumour site, and
histological subtype. For the detection of KIT mutations, genomic
DNA was extracted from paraffin-embedded tumour samples and
KIT exon 9 or 11 was amplified by PCR. Both forward and reverse
PCR products were sequenced and the results were compared with
normal sequences. One patient had two primary GISTs, which were
a high risk epithelioid gastric tumour lacking a KIT exon 9 and 11
mutation and a low risk spindle-cell small intestine tumour with
a KIT exon 11 mutation, respectively. Patient and tumour
characteristics are summarised in Table 1.
For the detection of Fas and FasL by western blotting, six frozen
primary GIST samples were pulverised and dissolved in ice-cold
PBS. After centrifugation at 18000g for 1min to remove debris,
the supernatant was collected. Western blot analysis was
performed as described above.
All tumour samples used in this study were handled according
to the guidelines of the Dutch Federation of Biomedical Scientific
Societies (FMWV) as described in ‘Code Proper Secondary Use of
Human Tissue’.
Tissue microarray construction
Representative regions of the paraffin-embedded primary
tumours were selected using H&E-stained slides and arrayed into
a tissue microarray (TMA), as described previously (Westra et al,
2005). Briefly, three 0.6mm tissue cores were taken from
(distinct) representative areas of each tumour specimen using
a manual tissue arrayer (Beecher Instruments, Sun Prairie, WI,
USA) and then transferred to a standard-size recipient
paraffin block. The array contained 161 tissue cores including
45 tumour samples in triplicate and 13 normal tissues
in duplicate, the latter serving as an internal control for
immunohistochemistry.
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sImmunohistochemistry
Sections of 4mm were taken from each array block and
deparaffinised in xylene. Immunohistochemistry was performed
as previously described (Arts et al, 2005). Antigen retrieval was
carried out by autoclaving sections in blocking solution (2%
blocking reagent (Roche Diagnostics, Mannheim, Germany) and
0.2% SDS in maleic acid buffer (pH 6.0)) at 1151C for three times
5min. Primary antibodies were mouse anti-Fas (clone CH-11,
1:100; Upstate Biotechnology, Lake Placid, NY, USA) and mouse
anti-FasL (clone 33, 1:160; BD Transduction Laboratories). As a
negative control, a serial section was processed without the addition
of primary antibody. Normal tissue samples within the TMA block
derived from liver and kidney served as positive controls for Fas
and FasL staining (Leithauser et al, 1993; Lee et al, 1999).
Staining analysis
Immunohistochemistry results were scored independently by two
observers (BR and AJHS) without knowledge of the clinicopatho-
logical data. As in each individual core all tumour cells showed the
same staining, cores were scored in a semiquantitative manner for
staining intensity: no staining (0), weakly positive staining (1),
positive staining (2), strong positive staining (3). Discrepant
scoring results were discussed under a multiheaded microscope to
achieve consensus. If cores from one tumour differed in staining
intensity, the median score of the three related cores determined
the score of the tumour. Furthermore, the staining pattern was
determined from each core.
Statistical analysis
Data analysis was performed using SPSS 12.0 software package for
windows (SPSS Inc., Chicago, IL, USA). Differences in distribu-
tions of Fas or FasL staining intensity and the different tumour
characteristics were evaluated by the w
2 test. To determine the
correlation between Fas and FasL staining, the spearman’s rank
test was used. A two-tailed P-value o0.05 was considered to be
significant.
RESULTS
MegaFasL-induced apoptosis in GIST cells
To evaluate whether Fas could be used as a target in GIST, we first
investigated Fas membrane expression in a panel of imatinib-
sensitive (GIST882) and imatinib-resistant (GIST48, GIST430 and
GIST430K-) cell lines. The cervical carcinoma cell line HeLa is
responsive to MegaFasL and was used as positive control (Holler
et al, 2003). Flow cytometry analysis revealed that all the GIST cell
lines had a high level of Fas membrane expression (Figure 1A). We
therefore tested the effectiveness of MegaFasL, a hexameric form of
sFasL. After as little as 6h of MegaFasL treatment, dose-dependent
apoptosis was observed in all the GIST cell lines. MegaFasL
induced substantially higher levels of apoptosis in GIST882,
GIST430, and GIST430K- than in HeLa, while nearly equal
amounts were observed in GIST48 compared to HeLa (Figure 1B
and C). Treatment of GIST882 and GIST48 with MegaFasL resulted
in caspase 8 activation and the disappearance of the inactive
proform of caspases 3 and 6. The active p19/p17 fragments of
caspase 3 were detected in both cell lines, although to a lesser
extent in GIST48, which is in agreement with the observed
difference in apoptosis levels between these two cell lines when
treated with 50ngml
 1 MegaFasL (53% apoptosis in GIST882 and
25% in GIST48; Figure 1C and D). The effect of MegaFasL was
dependent on caspase activation as zVAD-fmk, a pan-caspase
inhibitor, completely blocked apoptosis induction by this
compound (data not shown).
The effect of MegaFasL on imatinib-induced apoptosis
Following the identification of MegaFasL as a potent apoptosis-
inducing agent in GIST cells, we investigated its effect in
combination with imatinib. GIST882 pretreatment with MegaFasL
followed by the addition of imatinib, appeared to be the most
effective schedule. In this way, low concentrations of MegaFasL for
24h followed by the addition of imatinib for another 24h
substantially increased the amount of apoptosis compared to
levels seen with either MegaFasL or imatinib treatments alone
(Figure 2A). When imatinib was administered before MegaFasL,
no synergistic but rather an additive effect was observed (data not
shown).
Recently, Bauer et al (2006) showed that GIST48 cells are
relatively resistant towards imatinib. We therefore also evaluated
the combination of MegaFasL and imatinib in GIST48 by using the
same treatment schedule as GIST882. As in GIST882, synergistic
apoptosis induction was seen for the combination of MegaFasL
and imatinib, although higher concentrations of MegaFasL were
necessary to induce a substantial amount of apoptosis (Figure 2B).
Fas and FasL expression in GIST by
immunohistochemistry
As MegaFasL appeared to be an active agent in GIST cells, we
studied the expression of Fas and FasL in 45 GIST samples by
Table 1 Patient (n¼44) and tumour (n¼45) characteristics
n (%)
Sex
Male 19 (43)
Female 25 (57)
Age (years), median (range) 65.5 (36–87)
Risk classification
Very low risk 4 (9)
Low risk 13 (29)
Intermediate risk 13 (29)
High risk 15 (33)
Primary site
Stomach 29 (64)
Small intestine 12 (27)
Colon 3 (7)
Unknown 1 (2)
Histology
Spindle cell 37 (82)
Epithelioid 7 (16)
Mixed 1 (2)
Tumour size
p5cm 19 (42)
5–10cm 17 (38)
410cm 9 (20)
Mitotic figures
p5 per 50 HPF 38 (84)
45 per 50 HPF 7 (16)
KIT mutation
Exon 11 mutation 28 (62)
Exon 9 mutation 1 (2)
No exon 11 or 9 mutation 15 (33)
Unknown 1 (2)
Abbreviation: HPF¼high power fields.
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simmunohistochemistry using a TMA. Table 2 shows the overall
staining characteristics of Fas and FasL in the 45 GISTs tested. Fas
was detectable in all the tumour samples studied and was strongly
expressed in 62%. FasL expression was discerned in 89% of the
tumours with 27% staining strongly positive. A significant corre-
lation between Fas and FasL expression was found (spearman’s
correlation coefficient¼0.4, P¼0.006). Further statistical analysis
revealed that Fas and FasL staining intensity was not associated
with (1) risk classification, (2) primary site, (3) histological
subtype, (4) tumour size, (5) mitotic index, and (6) KIT mutation
status.
Both Fas and FasL immunohistochemical staining was pre-
dominantly cytoplasmic. The staining pattern for Fas was diffuse,
in contrast to FasL, which was mainly granular (Figure 3).
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Figure 1 Apoptosis induction by MegaFasL in GIST cell lines. (A) Analysis of Fas membrane expression by flow cytometry. The thin grey line represents
the IgG control and thick black line reflects the anti-Fas antibody. HeLa was used as a positive control. (B) Representative images of acridine orange staining
of GIST882 and GIST48 with or without treatment with 50ngml
 1 MegaFasL for 6h. Nuclear fragmentation is seen in cells treated with MegaFasL. (C) GIST
cell lines, and HeLa, were incubated with different concentrations of MegaFasL for 6h. Apoptosis was quantified with acridine orange staining. Data
represent the mean±s.d. of three independent experiments. (D) Expression of caspases 8, 6, 3, and cleaved caspase 3 after treatment of GIST882 and
GIST48 cells with 50ngml
 1 MegaFasL for 6h, analysed by western blot. Immunoblotting of actin was used as a loading control.
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In addition to immunohistochemistry, Fas and FasL protein
expression in six GIST samples and the GIST882 cell line was
evaluated by western blot analysis. HeLa was used as a positive
control (Hougardy et al, 2005). As shown in Figure 4, protein
products corresponding to the predicted molecular mass of
B36kDa for FasL were detected in HeLa, GIST882, and in all six
GISTs. The B48kDa Fas protein product was also detectable in
GIST882 and in all GIST samples. Furthermore, most GIST samples
– as well as the HeLa cell line – showed a lower band of B43kDa.
In addition, most of the GISTs featured an additional band that
migrated more slowly than the two bands shown in HeLa
(Figure 4). This additional B52kDa band could represent a highly
sialylated but functional form of Fas (Oehm et al, 1992; Keppler
et al, 1999).
DISCUSSION
The results of this study indicate that Fas may be a promising
therapeutic target in GIST. The GIST cell lines in our panel were
found to be highly sensitive to MegaFasL, which proved to be an
active apoptosis-inducing agent. Moreover, MegaFasL sensitised
GIST cells to imatinib-induced apoptosis. In addition to these
in vitro data, we found that each of 45 primary GISTs expressed
Fas, and most expressed FasL.
This is the first study investigating the role of death receptors in
the treatment of GIST. Both imatinib-sensitive (GIST882) and
imatinib-resistant GIST cell lines (GIST48, GIST430, and
GIST430K-) were responsive to MegaFasL. Furthermore, MegaFasL
sensitivity appeared to be independent of KIT expression because
the GIST430 cell line that expresses KIT was as sensitive to
MegaFasL as its KIT-negative daughter cell line. We found that low
concentrations of MegaFasL sensitised GIST cells to imatinib-
induced apoptosis. Notably, it appeared that the sequence of drug
delivery was important. Pretreatment of cells with imatinib
followed by incubation with MegaFasL had no more than an
additive effect. Reversing this schedule, however, resulted in
synergistic apoptosis induction. The underlying mechanism for
this observation remains unclear. Nimmanapalli et al (2001)
showed that the sensitising effect of imatinib to TRAIL in Bcr-Abl-
positive leukaemia cells was reduced when TRAIL was adminis-
tered after exposure to imatinib. Although imatinib causes cell
cycle arrest, it is unlikely that this mechanism is involved in the
reduced potentiation of MegaFasL-induced apoptosis by imatinib
pretreatment, as Fas-mediated apoptosis is not cell cycle
dependent (Hueber et al, 1998; Tepper et al, 2000). Possibly, KIT
inhibition by imatinib alters the membrane distribution of Fas,
making it less accessible for MegaFasL. Alternatively, the activated
caspase cascade by MegaFasL may induce cleavage of proteins
involved in cellular resistance to imatinib.
In our patient cohort, which was representative for an
unselected GIST population with regard to sex, age, tumour
localisation, histology, risk classification, and KIT exon 11
mutations (Corless et al, 2004; Nilsson et al, 2005), Fas and FasL
were abundantly expressed. Western blot analysis confirmed these
findings. Acquisition of FasL expression by tumour cells is one of
the mechanisms involved in tumour immune escape. Various
tumour types have been reported to express FasL, which can be
negatively correlated with prognosis as described for colon and
breast carcinomas (Reimer et al, 2000; Belluco et al, 2002). In our
study, 89% of the GISTs expressed FasL, but no correlation was
found with tumour size and mitotic index or risk groups based on
these prognostic factors, which predict metastatic behaviour. The
FasL staining pattern in the cytoplasm was granular, an expression
pattern that has also been observed in ovarian carcinoma and
melanoma, where FasL is stored in cytoplasmic microvesicles and,
upon release, induces apoptosis in Fas-bearing immune cells
(Andreola et al, 2002; Abrahams et al, 2003; Arts et al, 2005). FasL
could therefore be involved in the protection of GIST cells against
the immune system. In addition, we found a significant correlation
between Fas and FasL expression in GIST, which has been
observed in many other tumour types as well (Arts et al, 2005).
This co-expression has been implicated in tumour progression, as
FasL can act in an autocrine or juxtacrine Fas-dependent manner
to promote tumour growth (Lambert et al, 2003; Houston and
O’Connell, 2004). Further studies are needed to determine whether
such mechanisms also apply in GIST.
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Figure 2 The effect of MegaFasL on imatinib-induced apoptosis.
(A) GIST882 cells were pretreated with MegaFasL, as indicated, for 24h
followed by incubation with either DMSO-only or 1mM imatinib for an
additional 24h. Apoptosis was determined by acridine orange staining.
(B) GIST48 cells were treated with MegaFasL and/or imatinib, as described
in (A). Data represent the mean±s.d. of three independent experiments.
Table 2 Expression of Fas and FasL in GIST
Staining intensity Fas, n (%) FasL, n (%)
0 0 (0) 5 (11)
1 3 (7) 16 (36)
2 14 (31) 12 (27)
3 28 (62) 12 (27)
Total 45 (100) 45 (100)
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sGastrointestinal stromal tunour patients generally respond to
therapy with imatinib, which inhibits the KIT and PDGFRA
oncoproteins that appear to be initiating oncogenic events in most
GISTs. However, in the long run, most patients develop resistance
to imatinib therapy, as manifested by tumour progression. It
appears that, although imatinib treatment induces apoptosis and
causes cell cycle arrest of GIST cells, a fraction of the cells usually
survive, and these surviving cells may subsequently form the nidus
of an imatinib-resistant GIST, often containing secondary KIT
mutations (Antonescu et al, 2005; Heinrich et al, 2006). Therefore,
novel systemic therapeutic approaches are needed to maximise
GIST cell death. Targeting death receptors, such as Fas, is a
promising anticancer strategy by which apoptotic cell death can be
induced. Unfortunately, the introduction of therapies targeting Fas
with agonistic antibodies has been hampered by liver toxicity
(Ogasawara et al, 1993). However, the recently developed
MegaFasL is potentially less toxic and has been shown to be
active in several in vitro and in vivo models (Holler et al, 2003;
Greaney et al, 2006; Etter et al, 2007). MegaFasL is formed by
crosslinking two sFasL trimers resulting in a hexameric protein
that much more efficiently induces clustering of Fas on the cell
surface, leading to a higher degree of multimerisation of activated
receptors as compared with sFasL. As a consequence, a high local
concentration of the intracellular death domains might be formed,
leading to more efficient activation of caspase 8 after binding to
the adaptor molecule FADD (Holler et al, 2003).
We found that very low doses of MegaFasL potentiate the effect
of imatinib. Therefore, even when the therapeutic window is low,
systemic use of MegaFasL could still have a beneficial effect
in combination with imatinib. As many GISTs tend to metastasise
in the abdominal cavity, potential liver toxicity by MegaFasL might
be circumvented by intraperitoneal applications to prevent
MegaFasL from reaching high levels in the circulation (Stewart
et al, 2002; Etter et al, 2007). In this way, MegaFasL might be
applied in combination with systemic imatinib. The abundant Fas
expression in GISTs suggests that also MegaFasL alone might be an
option for patients with primary or acquired resistance to
imatinib. However, besides Fas membrane expression, one should
take in account the expression of intracellular components
affecting sensitivity to Fas-mediated apoptosis in these GISTs.
In conclusion, we have identified Fas as a uniformly expressed
receptor in GIST, which may be used as a therapeutic target. This
is supported by our in vitro studies, in which MegaFasL is a
potent apoptosis-inducing agent that is even more efficient in
combination with imatinib.
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Figure 3 Immunohistochemical staining for Fas and FasL in paraffin-embedded GIST samples. Representative examples of immunostaining for Fas (A and
B) showing predominantly diffuse cytoplasmic staining and FasL (C and D) showing granular cytoplasmic staining (magnification,  400).
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Figure 4 Expression of Fas and FasL in six resected GISTs and the
GIST882 cell line as determined by western blot analysis. HeLa served as a
positive control. GIST 2, 3, and 4 harbour a KIT exon 11 mutation, GIST 1,
5, and 6 have no KIT exon 9 or 11 mutations.
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